

JAGSONPAL PHARMACEUTICALS LIMITED
 Regd. Office : T-210J, Shahpur Jat, New Delhi 110049
 Unaudited Financial Results for the Quarter ended 30.06.2012

Rs. in lacs

Particulars	3 months	3 months	3 months	12 Months
	ended 30.06.2012	ended 31.03.2012	ended 30.06.2011	Ended 31.03.2012
	Unaudited	Audited	Unaudited	Audited
1 Income from operations				
a Net sales/Income from Operations (Net of excise duty)	3722.69	4146.19	4080.04	17651.39
b Other Operating Income				
Total Income from operations (net)	3722.69	4146.19	4080.04	17651.39
2 Expenses				
a Cost of materials consumed	1651.38	700.32	2081.44	7955.91
b Purchases of stock-in-trade	454.25	875.69	146.25	1572.28
c Changes in inventories of finished goods, work in progress and	-361.54	337.83	-183.21	-1073.60
d Employee benefits expenses	867.06	905.61	850.49	3650.73
e Depreciation and amortisation expense	65.18	58.00	57.93	253.58
f Other expenses	915.52	968.12	845.70	3884.60
Total expenses	3591.85	3845.57	3798.60	16243.50
3 Profit from Operations before Other Income, Finance Cost and Exceptional items (1-2)	130.84	300.62	281.44	1407.89
4 Other Income		11.57		36.92
5 Profit from ordinary activities before finance cost and Exceptional items (3+4)	130.84	312.19	281.44	1444.81
6 Finance Cost				
7 Profit from ordinary activities after finance cost but before Exceptional Items (5-6)	115.78	153.08	76.03	435.82
8 Exceptional Items				
9 Profit(+)/Loss(-) from Ordinary Activities before tax (7+8)	15.06	159.11	205.41	1008.99
10 Tax expense				
11 Net Profit/Loss(-) from Ordinary Activities after tax (9-10)	15.00	65.08	40.00	263.31
12 Extraordinary Items (net of tax expense Rs. lacs)		94.03	165.41	745.68
13 Net Profit(+)/Loss(-) for the period(11-12)	0.06	94.03	165.41	745.68
14 Share of profit/(Loss) of associates				
15 Minority interest				
16 Net Profit/(Loss) after taxes, minority interest and share of profit/(loss) of associates (13-14-15)	0.06	94.03	165.41	745.68
17 Paid up Eq. Sh. Cap.(Face value Rs. 5)	1309.90	1309.90	1309.90	1309.90
18 Reserves excluding Revaluation reserves as per Balance sheet of pr. Accounting yr				7208.47
19.i Earnings Per Share (before extraordinary items)				
a. Basic (Rs.)	0.00	0.36	0.63	2.85
b. Diluted (Rs.)	0.00	0.36	0.63	2.85
19.ii Earnings Per Share (after extraordinary items)				
a. Basic (Rs.)	0.00	0.36	0.63	2.85
b. Diluted (Rs.)	0.00	0.36	0.63	2.85
A PARTICULARS OF SHAREHOLDING				
1 Public Shareholding				
- Number of shares	8962360	8962360	8962360	8962360
- Percentage of Shareholding	34.21%	34.21%	34.21%	34.21%
2 Promoter and promoter group shareholding				
A Pledged / encumbered				
- Number of shares				
- Percentage of shares (as a % of the total shareholding of Promoter and promoter group)				
- Percentage of shares (as a % of the total share capital of the Company)				
B Non - encumbered				
- Number of shares	17235640	17235640	17235640	17235640
- Percentage of shares (as a % of the total shareholding of Promoter and promoter group)	100%	100%	100%	100%
- Percentage of shares (as a % of the total share capital of the Company)	65.79%	65.79%	65.79%	65.79%
B INVESTOR COMPLAINTS				
Pending at the beginning of the quarter	0			
Received during the quarter	3			
Disposed of during the quarter	3			
Remaining unresolved at the end of the quarter	0			

Notes

- The Unaudited Financial Results for the Quarter ended 30.6.2012 have been reviewed by the Audit Committee. The Board of Directors has approved the financial Results at its meeting held on 13.08.2012
- The Company is operating only in the Pharmaceuticals segment and hence compliance has been made under AS-17.
- The net effect of the deferred taxation for the Quarter as per AS-22 has been taken.
- Previous year figures have been regrouped / rearranged wherever necessary.



By Order of the Board
 For Jagsonpal Pharmaceuticals Limited

Rajpal Singh Kochhar
 Managing Director

Place : New Delhi
 Date : 13.08.2012

P.P. THUKRAL & CO.

CHARTERED ACCOUNTANTS

42, Ground Floor, World Trade Centre,
Babar Road, New Delhi - 110 001
Ph. (O) : 23413486
E-mail : sureshsethi62@yahoo.com

TO WHOM IT MAY CONCERN

We have reviewed the accompanying statement of un-audited financial results of Jagsonpal Pharmaceuticals Limited for the period ended 30.06.2012. This statement is the responsibility of the Company's management and has been approved by the Audit Committee and Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial statement issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of un-audited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.



Place : New Delhi
Date : 13/08/2012

for P. P. THUKRAL & CO.,
Chartered Accountants


SURESH SETHI
PARTNER

F.R. No. 000632 N
Membership no. 89318